CNBC Healthy Returns

Registration and Breakfast

Morning Sessions:

Welcoming Remarks

The Gatekeeper: Conversation with FDA Commissioner Scott Gottlieb

When he took the lead at the FDA, Scott Gottlieb, M.D., was seen as a pro-pharma choice. His legacy thus far, however, has been far more complicated. He’s taken on market inefficiencies, is approving generics at a record pace and trying to bring down drug prices. We’ll talk to him about what’s next at the FDA, including his vision for attacking the opioid crisis and his plans to balance public safety with faster drug approvals.
Scott Gottlieb, M.D., Commissioner of Food and Drugs, U.S. FDA
Interviewer: Meg Tirrell, Biotech and Pharma Reporter CNBC

The Investor Angle: What We’re Excited About Now

Leading investors give brief presentations on what they view as the most exciting and investable opportunities in health care for 2018 and beyond.
Private Equity: Todd B. Sisitsky, Managing Partner, TPG Capital
Venture Capital: Esther Dyson, Executive Founder, Way to Wellville; Board Member, 23 and Me and Open Humans Foundation
Private Investment: Andrew Farnum, Director of Program-Related Investments, Bill & Melinda Gates Foundation
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street,", CNBC

WWAD: What Will Amazon Do?

The news that Jeff Bezos’ behemoth was partnering with J.P. Morgan and Berkshire Hathaway to create a new health care venture sent health insurance stocks plummeting. It’s just a hint at Amazon’s potential disruptive, transformative role in health care. What’s next, and what’s their endgame?
Stephen Buck, CEO and Co-Founder, Courage Health ; Co-Founder, GoodRx
Bill George, Senior Founder Harvard Business School; Former Chairman and CEO, Medtronic
Julie Grant, Partner, Canaan Partners; Board Member, Biden Cancer Initiative
Moderator: Christina Farr, Technology and Health Reporter, CNBC.com

Onstage Demonstration (Speaker TBA)

Networking Break

Innovation at Scale: Is Bigger Better or Worse?

Many of the most innovative companies in the pharmaceutical industry today are smaller, more agile companies that focus on a limited number of technologies to drive innovation. Often, the main way big pharma companies are innovating is by buying the upstarts. Is there an inverse relationship between company size and success of innovation?
Abbie Celniker, Ph.D., Partner, Third Rock Ventures
Fred Hassan Special Limited Partner, Warburg Pincus; Chairman, Caret Group; Former Chairman and CEO, Schering-Plough
Jeff Jonas, M.D., CEO, SAGE Therapeutics
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street,", CNBC

Getting Personal: Why it Matters (Speaker TBA)

Anyone who works in health care —investor, doctor, executive — has, at his or her core, a central mission: to improve medical outcomes. Here’s one patient whose life was saved by cutting-edge treatment.

I Wanna Live Forever: A Conversation with Craig Venter

One of the leading scientists of our time, J. Craig Venter has been on the cutting edge of science for over two decades. His institute is a leading research organization dedicated to genomic research, and he’s the co-founder, chairman and CEO of Human Longevity. We’ll find out what this visionary sees on the horizon in health care, science and medicine.
J. Craig Venter, Ph.D., Co-Founder, Executive Chairman and CEO, Human Longevity; Founder, Executive Chairman and CEO, J. Craig Venter Institute
Interviewer: Joe Kernen, Co-Anchor, “Squawk Box,” CNBC

Lunch

Join us for lunch in the Terrace Room on the lobby level. Select tables will feature hosted discussions. Please see your programs and posted information for details.

Afternoon Sessions:

Capitalizing Cures: Do Investors Inhibit Innovation?

It costs billions of dollars to develop revolutionary treatments and cures at scale, and often the only place to get that much funding is in the public markets. Investors, however, are focused on quarterly results and often have little patience with clinical trial setbacks and the years-long process of developing drugs. Is there a way to address this conflict?
Tony Coles, M.D., Chairman and CEO, Yumanity Therapeutics
Alex Denner, Ph.D., Founding Partner and CIO, Sarissa Capital Management
Leonard S. Schleifer, M.D., Ph.D., Founder, President and CEO, Regeneron Pharmaceuticals
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street," CNBC

The Opioid Crisis: A Reckoning

The opioid crisis is a public health crisis of historic proportions; not since the HIV/AIDS epidemic has the United States faced as devastating and lethal a problem. And expensive, with the price tag soaring to more than $1 trillion. Now, the man who successfully took on the tobacco companies, forcing them into a $246 billion settlement, has opioid makers like Purdue Pharma in his crosshairs. And this time it’s personal.
Mike Moore, Partner, Mike Moore Law Firm; former Attorney General, State of Mississippi
Interviewer: TBA

Onstage Demonstration (Speaker TBA)

Aligning Interests: Moving from Volume to Value

Many health economists and insurance companies seek a change from fee-for-service, which incentivizes providers to conduct more tests and provide more treatment, to an outcome-based model, offering incentives for successful and efficient treatments. Quality over quantity. How can providers and payers (and employers) come together to make this new model work at scale?
David Cordani, President and CEO, Cigna
Delos ‘Toby’ Cosgrove, M.D., Former President and CEO, The Cleveland Clinic
Moderator: Bertha Coombs, Correspondent, CNBC

Networking Break

Getting Personal: Why it Matters Part 2 (Speaker TBA)

Data vs. Disease: New Approaches

Cancer: Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer and SVP, Oncology, Flatiron Health
Diabetes: Jessica L. Mega, M.D., M.P.H., Chief Medical Officer, Verily Life Sciences
Interviewer: Meg Tirrell, Biotech and Pharma Reporter, CNBC

Closing Session TBA

Cocktail Reception